Solvent/Detergent-Treated Human Plasma
As part of this pilot project, the Canadian Agency for Drugs and Technologies in Health (CADTH) reviewed clinical, cost-effectiveness, and ethical information regarding solvent/detergent-treated human plasma (S/D plasma) (Octaplas), which can be used as an alternative to standard plasma.
Based on the evidence, CADTH’s Panel of Experts developed a recommendation for the optimal use of S/D plasma in high-risk populations; i.e., patients who need a high volume of transfusions annually because they have one of the following chronic hematological conditions:
- thrombotic thrombocytopenic purpura (TTP)
- hemolytic uremic syndrome (HUS)
- clotting factor deficiencies for which no specific concentrates are available (e.g., factor V, factor XI, factor XIII).
By reviewing the evidence and developing the optimal use recommendation, CADTH is providing health professionals, policy decision-makers, and consumers with the evidence-based resources they need to make sound decisions in this therapeutic area.
S/D plasma may be considered as an alternative to standard plasma for certain patients who need a high volume of transfusions annually because they have one of the following conditions:
- TTP (both congenital and acquired forms)
- HUS with associated factor H deficiency
- or clotting factor deficiencies for which specific licensed concentrates may not be readily available (e.g., factor V, factor XI, factor XIII)
- have experienced an allergic reaction to frozen plasma, or
- have a pre-existing lung disorder, or
- need frozen plasma, but a blood group−compatible product is not available in a timely manner.